Premium
COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY
Author(s) -
Tam C.S.,
Roberts A.W.,
Anderson M.,
Dawson S.,
Hicks R.,
Burbury K.,
Turner G.,
Di Iulio J.,
Bressel M.,
Westerman D.,
Agarwal R.,
Pott C.,
Dreyling M.,
Dawson M.,
Seymour J.F.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_134
Subject(s) - medicine , ven , clinical endpoint , adverse effect , venetoclax , surrogate endpoint , phases of clinical research , neutropenia , gastroenterology , refractory (planetary science) , mantle cell lymphoma , nuclear medicine , surgery , lymphoma , clinical trial , chemotherapy , leukemia , physics , computer security , chronic lymphocytic leukemia , astrobiology , computer science